Polomar Health Services, Inc.

Polomar Health Services, Inc.

PMHS
Polomar Health Services, Inc.US flagOther OTC
0.08
USD
-0.04
- -
2.24MMarket Cap
Polomar Health Services, Inc.
PMHS
(Other OTC)

Recent

price

0.08

P/E

ratio

- -

div

yld

- -

ROIC.AI

2007
2008
2009
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
0.02
0.06
Revenue per Share
-1.16
-3.69
-2.18
- -
-0.02
-0.05
-0.39
-0.37
Basic EPS, GAAP
-1.16
-3.69
-2.18
- -
-0.02
-0.04
-0.01
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-13.98
-17.67
-19.85
-0.02
-0.06
-0.1
-0.49
-0.49
Book Value per Share
1.81
0.32
0.89
- -
- -
-0.04
-0.04
-0.04
Tangible Book Value per Share
- -
- -
- -
45
26
28
28
28
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
1
2
Sales/Revenue/Turnover
- -
- -
- -
-525.55
-1,053.51
-2,209.13
-1,627.55
-614.95
Operating Margin (%)
- -
- -
- -
- -
- -
- -
10
10
Depreciation Expense
- -
- -
- -
- -
-1
-1
-11
-10
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
-524.6
-1,405.21
-2,280.25
-1,650.82
-622.7
Profit Margin (%)
- -
- -
- -
- -
- -
-1
-1
-1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
- -
9
-1
-1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
28
28
28
Market Capitalization
6
22
4

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
2
Payables & Accruals
- -
- -
1
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-3,451.01%
-114.21%
Free Cash Flow
- -
262.84%
-64.35%
Net Income, GAAP
- -
364.56%
697.8%
Sales/Revenue/Turnover
- -
- -
1,001.98%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
1
1
2026
1
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.01
-0.01
-0.01
- -
-0.05
2025
-0.02
-0.02
-0.02
- -
-0.39
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Polomar Health Services, Inc. engages in retail compounding pharmacy services and online platforms for prescription fulfillment and weight-management medications, with operations anchored in the United States. Founded in the early 2020s, the company maintains its headquarters in [headquarters location not publicly disclosed in available sources], and seeks to expand through online platforms and third-party telehealth partnerships to broaden access to pharmaceutical products and services. Main products and services - Retail compounding pharmacy services: customized prescription compounding for individual patients, including sterile and non-sterile formulations. - Online platforms for prescription fulfillment: digital interfaces that connect patients with licensed providers and pharmacies to process and dispense medications prescribed via telehealth channels. - Weight management medications platform: SlimRx, an online prescribing and fulfillment channel for weight loss medications, including semaglutide-based therapies, with physician-assisted prescription pathways. - Upcoming and planned product lines: PoloMeds, a planned extension to fulfill prescriptions for diabetes medications, erectile dysfunction therapies, and exclusive dermatological formulations; dermatology-focused compounding and product offerings. Latest major changes - Strategic partnerships and alliances: expands prescription fulfillment through third-party telehealth platforms; ongoing collaborations to broaden geographic reach and regulatory clearance for cross-state operations. - Product launches and expansions: SlimRx operates as the existing online platform for weight loss medications; PoloMeds is planned for launch in 2025 to broaden product and therapy categories, including diabetes and dermatology medications. - Corporate and regulatory changes: pursuing state-by-state expansion of pharmacy operations; seeking regulatory approvals and export permits to enable international or cross-border pharmacy activities; adjustments to corporate staffing to support regulatory, legal, and compliance functions. Industry context and geography - Industry: retail pharmacy services with a focus on telehealth-enabled prescription fulfillment and online medication platforms. - Segments: retail compounding, telehealth fulfillment services, weight-management pharmacotherapy platforms, specialty dermatology and diabetes medication offerings. - Markets: United States, with plans for expansion to additional states and potential export pathways; headquarters and primary operations located in the United States, with public disclosures indicating a regulatory and licensing emphasis for growth. - Corporate relationships: operates as an independent company focused on pharmacy services, with potential collaborations and licensing agreements to access proprietary formulations and delivery capabilities. Founding and leadership context - Founding year: early 2020s (specific year not consistently disclosed in public summaries). - Headquarters: United States-based (exact city not consistently disclosed in public disclosures). Subsidiaries and brands - SlimRx: online platform connecting patients with licensed physicians to obtain weight loss medications. - PoloMeds: planned platform to fulfill a broader range of prescription therapies, including diabetes, erectile dysfunction medications, and exclusive dermatology formulations. Notes - The company reports a focus on expanding its wholesale and telehealth fulfillment capabilities, leveraging strategic partnerships and new product launches to accelerate growth, while navigating regulatory requirements across states. Citations - Polomar Health Services, Inc. operates retail compounding pharmacy services and third-party telehealth prescription fulfillment platforms, including SlimRx, with plans for PoloMeds expansion; multiple sources reference its online platform strategy and weight-management medication focus. - Public disclosures indicate ongoing strategic partnerships with third-party telehealth platforms and plans to expand pharmacy operations state-by-state, plus regulatory and licensing initiatives to support growth. - Market data and company profiles summarize SlimRx as an online platform for weight loss medications and note PoloMeds as a forthcoming product line with expanded therapy offerings.

Company News

APIChatGPT
  • Fastbase Inc. Ventures into Artificial Intelligence to Elevate Its Data-Driven Marketing Solutions

  • Trustfeed Corp (OTC:TRFE) Confirms effectiveness of its Form 10 filing